Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
HER2DX reflects key biological and pathologic features of HER2+ breast cancer and independently predicts pCR, supporting its utility for individualized treatment decision-making.
Authors
- Pedro Jares (ORCID: https://orcid.org/0000-0002-8401-579X)
- Fara Brasó‐Maristany (ORCID: https://orcid.org/0000-0001-5440-9643)
- Juan Miguel Cejalvo (ORCID: https://orcid.org/0000-0002-8755-8626)
- Sandra Cobo (ORCID: https://orcid.org/0000-0002-9672-100X)
- R Gómez-Bravo (ORCID: https://orcid.org/0009-0000-4090-4395)
- Marta Tapia (ORCID: https://orcid.org/0000-0002-0266-1289)
- Blanca González‐Farré (ORCID: https://orcid.org/0000-0002-1796-7248)
- Rodrigo Sánchez-Bayona (ORCID: https://orcid.org/0000-0002-5255-6620)
- Jesús Soberino (ORCID: https://orcid.org/0009-0004-4035-7669)
- Anabel Martínez-Romero (ORCID: https://orcid.org/0000-0001-5626-6674)
- Francisco J. Pardo-Palacios (ORCID: https://orcid.org/0000-0002-3067-0166)
- Eva Hernández‐Illán (ORCID: https://orcid.org/0000-0002-4022-0548)
- Javier Cortés (ORCID: https://orcid.org/0000-0001-7623-1583)
- Joel S. Parker (ORCID: https://orcid.org/0000-0003-2080-6901)
- Olga Martínez‐Sáez (ORCID: https://orcid.org/0000-0001-8686-0236)
- Cristina Tebar (ORCID: https://orcid.org/0000-0001-5012-0615)
- Esther Sanfeliu (ORCID: https://orcid.org/0000-0002-7974-3346)
- Laia Paré (ORCID: https://orcid.org/0000-0002-4904-558X)
- Kepa Amillano (ORCID: https://orcid.org/0000-0002-4961-9328)
- Santiago Escrivá-de-Romaní (ORCID: https://orcid.org/0000-0001-7816-7589)
- Eva Ciruelos (ORCID: https://orcid.org/0000-0002-2796-1042)
- Patricia Villagrasa (ORCID: https://orcid.org/0000-0002-8662-3641)
- Cristina Saura (ORCID: https://orcid.org/0000-0001-8296-5065)
- Wesley Buckingham (ORCID: https://orcid.org/0009-0006-4707-9803)
- Mercedes Marín‐Aguilera (ORCID: https://orcid.org/0000-0002-2205-3459)
- Serafin M. Morales (ORCID: https://orcid.org/0000-0001-7445-4193)
- Montserrat Muñoz-Mateu (ORCID: https://orcid.org/0000-0001-7772-1437)
- Aleix Prat (ORCID: https://orcid.org/0000-0003-2377-540X)
- Joan Anton Puig‐Butillé (ORCID: https://orcid.org/0000-0003-4345-9631)
Institutions
- University of North Carolina at Chapel Hill (US)
- Breast Cancer Research Foundation (US)
- Hospital Universitari Arnau de Vilanova (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Hospital Universitario 12 De Octubre (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Fomento de Construcciones y Contratas (Spain) (ES)
- Hospital Quirónsalud Barcelona (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital Arnau de Vilanova (ES)
- Genomics Medicine (Ireland) (IE)
- Solti (ES)
- Oryzon Genomics (Spain) (ES)
- Hospital Universitari Sant Joan de Reus (ES)
- Fundació Clínic per a la Recerca Biomèdica (ES)
- INCLIVA Health Research Institute (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Vall d'Hebron Institute of Oncology (ES)
- Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3123
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Breast Cancer Research Foundation
- European Commission
- Fundación Científica Asociación Española Contra el Cáncer
- Fundación Fero
- Instituto de Salud Carlos III